Triplet Succeeds in Colorectal Cancer.
A drug trio consisting of BRAF, MEK, and EGFR inhibitors may become the new standard of care in BRAF-mutant metastatic colorectal cancer. In the phase III BEACON CRC trial, encorafenib, binimetinib, and cetuximab significantly extended overall and progression-free survival and increased the objective response rate compared with cetuximab plus chemotherapy.